• Cancel
    Date：2024-10
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=854

    Recently, Dingzhi Dental, a leading brand and expert in complex dental implants in China, announced the closing of its Series A financing, raising several hundred million RMB, with Eight Roads as the sole investor. CEC Capital served as the exclusive

  • Cancel
    Date：2024-10
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=848

    Wuhan-based iRegene, which aims to become a global leader in universal chemically induced cell therapy, recently announced the closing of its Series B financing, raising several hundred million RMB. The round was co-led by Orinno Capital and CDBT Group, w

  • Cancel
    Date：2024-08
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=842

    MicroCyto announced that it has raised over 300 million yuan in Series A financing. The round was led by Beijing Jingguorui Investment, with participation from Beijing Medical and Health Industry Investment Fund, Shenzhen Capital Group, and Hebei Producti

  • Cancel
    Date：2024-07
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=839

    MoonBiotech announced that it has recently completed a RMB 300 million Series C+ financing, solely invested by SDIC JULI Investment Management Co., LTD. This financing round follows the Series C funding involving SDIC Venture Capital, marking another inst

  • Cancel
    Date：2024-05
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=775

    Recently, Blue Sail Medical (002382.SZ) announced that its cardiovascular and cerebrovascular business unit, Blue Sail Biosensors, has raised a total of RMB 1 billion in funding. The Series A2 round introduced an additional RMB 100 million, following a RM

  • Cancel
    Date：2024-05

    Exclusive Financial Advisor to MagAssist

  • Cancel
    Date：2024-05
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=773

    Recently, Vision Medicals announced a successful completion of D+ round funding worth hundreds of millions RMB, with Kequan Fund as lead-investor and Tianxin Fund as co-investor. Funds raised in this round will be primarily used to promote the research an

  • Cancel
    Date：2024-03

    Exclusive Financial Advisor to HYGIEIA

  • Cancel
    Date：2024-02
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=771

    On February 21, 2024, Yantai Dongcheng Biochemicals (002675) announced that its wholly-owned subsidiary, Yitai Pharmaceutical, intends to purchase the 99mTc-GSA injection and GSA cold kit (hereinafter referred to as the "target product") held by Rongcheng